Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arch Biopartners (TSE:ARCH)
TSXV:ARCH
Holding TSE:ARCH?
Track your performance easily
ARCH Stock Chart & Stats
Day’s RangeC$0 - C$0
52-Week RangeC$1.36 - C$2.56
Previous CloseC$1.77
Volume11.50K
Average Volume (3M)15.74K
Market Cap
C$114.80M
Enterprise ValueC$120.07M
Total Cash (Recent Filing)C$43.95K
Total Debt (Recent Filing)C$5.31M
Price to Earnings (P/E)―
Beta1.32
Next Earnings
Feb 04, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding64,650,633
10 Day Avg. Volume17,334
30 Day Avg. Volume15,736
Standard Deviation0.19
R-Squared0.05
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)-17.70
Price to Sales (P/S)52.39
Price to Cash Flow (P/CF)-33.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Options Prices
Currently, No data available
---
Ownership Overview
ARCH FAQ
What was Arch Biopartners’s price range in the past 12 months?
Arch Biopartners lowest stock price was C$1.36 and its highest was C$2.56 in the past 12 months.
What is Arch Biopartners’s market cap?
Currently, no data Available
When is Arch Biopartners’s upcoming earnings report date?
Arch Biopartners’s upcoming earnings report date is Feb 04, 2025 which is in 44 days.
How were Arch Biopartners’s earnings last quarter?
Arch Biopartners released its earnings results on Aug 29, 2024. The company reported -C$0.014 earnings per share for the quarter, beating the consensus estimate of -C$0.02 by C$0.006.
Is Arch Biopartners overvalued?
According to Wall Street analysts Arch Biopartners’s price is currently Overvalued.
Does Arch Biopartners pay dividends?
Arch Biopartners does not currently pay dividends.
What is Arch Biopartners’s EPS estimate?
Arch Biopartners’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Arch Biopartners have?
Arch Biopartners has 64,858,350 shares outstanding.
What happened to Arch Biopartners’s price movement after its last earnings report?
Arch Biopartners reported an EPS of -C$0.014 in its last earnings report, beating expectations of -C$0.02. Following the earnings report the stock price went up 1.399%.
Which hedge fund is a major shareholder of Arch Biopartners?
Currently, no hedge funds are holding shares in TSE:ARCH
---
Arch Biopartners Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
26.42%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
8.66%
Trailing 12-Months
Company Description
Arch Biopartners
Arch Biopartners Inc is a clinical stage company developing technologies with the potential to make medical or commercial impacts. The company is developing a drug platform Metablok to produce drug candidates to inhibit organ inflammation caused via the DPEP-1 pathway. Its under development portfolio is AB569, a potential new treatment for antibiotic resistant bacterial infections in the lungs or wounds; and, Borg peptide coatings that increase corrosion resistance and decrease bacterial biofilm on various medical grade metals and plastics.
---
Technical Analysis
---